Repair Foundation (MRF) today announced the achievement of a myelin
repair Phase 1 clinical trial for multiple sclerosis earlier than the
foundation's goal set for 2014. By establishing its Accelerated
Research Collaboration (ARC) Model to advance myelin repair
treatments forward into clinical trial Phase 1 within a decade, the
Myelin Repair Foundation achieved this critical milestone ahead of its
goal, validating the efficiency of the ARC model to speed drug
This Phase 1 clinical trial conducted at Cleveland Clinic will examine
the efficacy of a new myelin repair therapeutic pathway with mesenchymal
stem cells (MSCs), based on MRF supported research conducted by MRF
Principal Investigator Dr. Robert Miller, Professor of Neurosciences and
Vice President for Research & Technology Management at Case Western
Reserve University. To date, half of the 24 patients planned for this
initial trial have been enrolled.
"Scientists hope that one day their research will reach clinical trials,
and I'm thrilled to achieve this milestone in my career," said Dr.
Robert Miller. "Without the support of Myelin Repair Foundation funding
a critical component of our research that is the basis of this trial,
this achievement would not have been possible. Our partnership with the
Myelin Repair Foundation has helped identify new pathways to treat
disease that reverses damage, ultimately accomplishing so much more than
the suppression of MS symptoms."